Celcuity (NASDAQ:CELC) Upgraded to Hold at Wall Street Zen

Celcuity (NASDAQ:CELC) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research analysts also recently commented on the stock. Jefferies Financial Group increased their price target on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Wolfe Research reissued an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research note on Thursday, March 12th. Stifel Nicolaus upped their price objective on Celcuity from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, January 21st. Finally, Wells Fargo & Company began coverage on Celcuity in a report on Friday, December 12th. They issued an “overweight” rating and a $126.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Celcuity currently has an average rating of “Moderate Buy” and a consensus target price of $109.88.

Celcuity Price Performance

Celcuity stock opened at $106.02 on Friday. Celcuity has a 52-week low of $7.57 and a 52-week high of $120.32. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The firm’s fifty day moving average is $109.49 and its 200 day moving average is $90.74. The company has a market cap of $4.91 billion, a price-to-earnings ratio of -27.97 and a beta of 0.38.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.09. Sell-side analysts forecast that Celcuity will post -2.62 EPS for the current fiscal year.

Insider Transactions at Celcuity

In related news, Director David Dalvey sold 20,000 shares of the stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the transaction, the director owned 90,000 shares of the company’s stock, valued at $10,802,700. This represents a 18.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 15.77% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Celcuity

Hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its position in shares of Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after buying an additional 319 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Celcuity in the fourth quarter worth about $42,000. Ogorek Anthony Joseph NY ADV purchased a new stake in Celcuity in the third quarter worth about $27,000. US Bancorp DE grew its holdings in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares in the last quarter. Finally, NBC Securities Inc. bought a new position in Celcuity during the 4th quarter worth about $99,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.